Mercury Laboratories Limited

MERCURYLAB6

INE947G01011

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:52 28/05/2024 pm IST			5-day change	1st Jan Change
896.5 ^INR	+3.64%		+0.73%	-12.93%

28/05	Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
12/02	Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Mercury Laboratories Limited Recommends Dividend for the Year 2022-23

May 05, 2023 at 05:10 pm IST

Mercury Laboratories Limited recommended dividend @ 35% (INR 3.50 per share) on the Equity Share Capital for the year 2022-23 subject to approval of shareholders at an ensuing Annual General Meeting.

Latest news about Mercury Laboratories Limited

Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	28/05	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Mercury Laboratories Names COO	09/11	MT
Mercury Laboratories Limited Announces Promotion of Saurabh Mittal as Chief Operating Officer	08/11	CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31,2023	28/23/28	CI
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	05/23/05	CI
Mercury Laboratories Limited Recommends Dividend for the Year 2022-23	05/23/05	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/23/13	CI
Mercury Laboratories Limited Approves Creation of New Facility for Manufacturing Small Volume Parenteral(SVPs) At Jarod	12/22/12	CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/22/11	CI
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2022	27/22/27	CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	09/22/09	CI
Mercury Laboratories Limited Recommends Dividend for the Year 2022	26/22/26	CI
Mercury Laboratories Limited Announces Resignation of Kinjal Khandelwal as Company Secretary and Compliance Officer	21/22/21	CI
Mercury Laboratories Limited Approves Appointment of Mr. Ashish Vasavada, as Chief Financial Officer	21/21/21	CI
Mercury Laboratories Approves Interim Dividend and Final Dividend for the Year Ended March 31, 2021	28/21/28	CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	10/21/10	CI
Mercury Laboratories : Crisil Affirms FB+ Rating on Mercury Laboratories' Fixed Deposits; Outlook Stable	18/21/18	MT
Mercury Laboratories' : CFO Tenders Resignation	28/21/28	MT
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	27/21/27	CI
Mercury Laboratories Limited Recommends Dividend for Year Ended March 31, 2021	27/21/27	CI
Mercury Laboratories Limited Announces Resignation of Enu Khandelwal as CFO with Effect from June 22, 2021	27/21/27	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	11/21/11	CI
Mercury Laboratories Limited Declares an Interim Dividend for the Financial Year 2020-21	11/21/11	CI

Chart Mercury Laboratories Limited

Duration

Period

More charts

Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. The Company is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, among others. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCURY LABORATORIES LIMITED	-12.93%	12.49M
MERCK KGAA	+16.34%	79.03B
KYOWA KIRIN CO. LTD.	+8.48%	8.78B
SK BIOPHARMACEUTICALS CO., LTD.	-16.33%	4.83B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.22%	4.65B
YUHAN CORPORATION	+2.18%	3.89B
INDIVIOR PLC	+20.51%	2.34B
BETTA PHARMACEUTICALS CO., LTD.	-26.79%	2.18B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.12%	2.11B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.56%	2B